May 18, 2023
Eisai estimates that the annual societal value of its Alzheimer’s disease (AD) modifying therapy lecanemab at nearly 4.7 million yen per patient, combining the impacts of both improvement in health outcomes and reduction in costs. The Japanese pharma said on...read more